GLP-1 Medications and Cancer Risk: The Honest Facts
There is a thyroid boxed warning based on rodent studies and specific contraindications. Here is the careful, honest picture.
The short answer
Semaglutide and tirzepatide carry an FDA boxed warning about thyroid C-cell tumors seen in rodent studies. It is not known whether they cause medullary thyroid carcinoma (MTC) in humans. They are contraindicated if you have a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). For other cancers, large studies have been broadly reassuring, and obesity itself raises the risk of several cancers.
What the warning means and does not mean
The thyroid signal came from rodents given high doses; a human causal link has not been established. The responsible response is screening, not panic: a physician asks about thyroid cancer and MEN2 history before prescribing, and these medications are not used in people with those histories.
Ready to start?
$199 Skeptics' Trial, see if it works for you
One-time $199 trial with physician evaluation and, only if a prescription is approved and the dispensing pharmacy can fulfill it for the patient's location, one month of compounded semaglutide; the pharmacy confirms packaging and shipping details before fulfillment. No long-term commitment. Standard care starts with a $119 physician review; medication is separate, and compounded semaglutide programs start at $166/month.
Start the 30-day trialThe bigger picture
Carrying excess weight is itself a well-established risk factor for multiple cancers. For most eligible patients, supervised weight loss is part of reducing long-term health risk. This is a conversation to have honestly with your physician, weighing your individual history.
How this relates to what we offer
Our $119 review screens for thyroid cancer and MEN2 history and other contraindications before any plan. We will not prescribe when it is not appropriate, and we explain the boxed warning plainly.
What you can start today at New Hope Weight Loss
After a one-time $119 medical review with Dr. Sharma, eligible patients begin physician-supervised compounded semaglutide from $166 a month or compounded tirzepatide from $233 a month, with a $199 one-month Skeptics' Trial. Compounded semaglutide and tirzepatide are not FDA-approved or brand-identical and have not undergone FDA premarket review for safety, effectiveness, or quality. Results vary. Any prescription depends on individualized medical review and lawful pharmacy fulfillment for the patient's location. In person in Orange County and by telehealth for eligible patients in California.
Frequently asked questions
Do GLP-1 medications cause cancer?
There is an FDA boxed warning about thyroid C-cell tumors based on rodent studies; a human causal link has not been established. They are contraindicated with a personal or family history of medullary thyroid cancer or MEN2.
Who should not take a GLP-1 because of cancer risk?
People with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2) should not take these medications. A physician screens for this.
What about other cancers?
Large studies have been broadly reassuring for other cancers, and obesity itself is a well-established risk factor for several cancers. Discuss your individual history with your physician.
Should the thyroid warning scare me off?
The signal came from high-dose rodent studies, not proven human cause. The responsible step is screening, which is exactly what a physician does before prescribing.
Does New Hope screen for this?
Yes. The $119 review screens for thyroid cancer and MEN2 history and other contraindications before any plan, and we explain the boxed warning plainly.
This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.